Amylyx Secures Long-Term Avexitide Manufacturing with Bachem and Polypeptide
AMLX has more than doubled off its 52-week low of $10.07.
Summary
Amylyx entered into manufacturing and supply agreements with Bachem and Polypeptide for long-term commercial supply of avexitide, including a $30 million upfront fee to Polypeptide and minimum purchase commitments beginning in 2028.
Key Events · M&A and Partnerships · AMLX
-
Dual Manufacturing Agreements Secured
Amylyx entered into a Manufacturing and Supply Agreement with Bachem Americas and a term sheet with Polypeptide Group AG for long-term commercial supply of avexitide drug substance, with both acting as non-exclusive suppliers.
-
$30M Upfront Capacity Fee
The Polypeptide term sheet requires a $30 million upfront fee for capacity reservation, with minimum purchase commitments beginning in 2028.
-
Supply Commitments Begin 2028
Both agreements include binding minimum annual purchase quantities of avexitide drug substance starting in 2028, with annual price adjustments for labor, utilities, and overhead.
-
Commercial Launch Preparation
These agreements follow positive Phase 3 LUCIDITY trial results for avexitide and the recent $500 million upsized public offering, positioning the company for potential regulatory approval and commercial launch.
Analysis · AMLX · Life Sciences
Ahead of a potential commercial launch, Amylyx has locked in two non-exclusive manufacturing partners for avexitide, its lead drug candidate that recently delivered positive Phase 3 results. The Bachem agreement includes binding minimum purchase commitments starting in 2028, while the Polypeptide term sheet requires a $30 million upfront capacity reservation fee. These agreements de-risk the supply chain, but the $30 million upfront payment and future minimum purchase obligations represent a meaningful capital commitment for a company that just raised $500 million to fund commercialization.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMLX was trading at $33.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $10.07 to $41.14. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.